The linearly decreasing convergence factor a. حسب Junhao Wei (6816803)

Stability differences between condition 1 and other conditions across participants on the non-hemiparetic side (NHP) side. حسب Hyung Suk Yang (20442438)

الموضوعات:

Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf حسب Mi-Ae Lyu (20413646)

"…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…"

Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf حسب Mi-Ae Lyu (20413646)

"…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…"

Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf حسب Mi-Ae Lyu (20413646)

"…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…"

Stability differences between condition 1 and other conditions across participants on the hemiparetic (HP) side. حسب Hyung Suk Yang (20442438)

الموضوعات:

Overview of the WeARTolerance program. حسب Ana Beato (20489933)

الموضوعات:

Voxel-based whole-brain analysis shows regional and dose-dependent effects of netoglitazone in decreasing plaque count. حسب Francesca Catto (21253435)

"…Additionally, the plots on the right side display the average plaque count across the cohorts. …"

Brain regions with significantly decreased activations for the Raven task are shown in blue. حسب Morteza Fattahi (15892028)

Schematic representation of the study protocol. حسب Neng Pan (5262032)

الموضوعات:

Baseline characteristics. حسب Neng Pan (5262032)

الموضوعات:

Comparison within groups. حسب Neng Pan (5262032)

الموضوعات:

Comparison before and after the experiment in each group. حسب Neng Pan (5262032)

الموضوعات:

Data ste. حسب Neng Pan (5262032)

الموضوعات:

Comparison of data after the experiment. حسب Neng Pan (5262032)

الموضوعات:

Correlation diagram of each parameter in each group. حسب Neng Pan (5262032)

الموضوعات:

Recruitment process. حسب Neng Pan (5262032)

الموضوعات:

Comparison of post-experimental outcome measures. حسب Neng Pan (5262032)

الموضوعات:

ALK inhibitors (Positive control) and ABT199 (Proposed binding) in complex with the ALK active side. حسب Richard Junior Zapata Dongo (17912565)

Bluetooth beacons with colour coded lanyards. حسب J Mark Ansermino (13958512)

الموضوعات: